3 British Biotech Stocks With Analyst Upside Over 20%

UK households have absorbed almost £14,000 of extra bills since 2021, so cash is tighter and every pound put into the market has to work harder. That pressure creates a sharper focus on British biotech stocks with solid balance sheets and sensible valuations. This article walks through three candidates from the screener that could help you get targeted exposure to higher risk, higher potential biotech ideas.

The three stocks below are a small slice of the idea, and the full screen on Simply Wall St surfaced three more UK biotech companies with equally compelling stories that are not covered here. If you want to move beyond this starter list and identify your own high-conviction biotech plays, head straight to the Biotech Stocks screener.

Hikma Pharmaceuticals (LSE:HIK)

Overview: Hikma Pharmaceuticals develops and supplies generic, specialty and branded medicines, with a key biotech link through hospital injectable and oncology treatments.

Operations: Hikma generates most of its revenue from Injectables at US$1.4b, followed by Hikma Rx at US$1.0b and Branded at US$914 million.

Market Cap: £3.3b

For the Biotech Stocks theme, Hikma Pharmaceuticals matters because its hospital injectable and oncology franchise ties higher risk drug development to a large, diversified pharma platform.

"Continued emphasis on high-value, complex generics and specialty injectables, supported by both internal R&D and strategic acquisitions (such as Xellia), reflects the increasing adoption of generics by healthcare systems seeking cost containment. This provides Hikma with exposure to higher-margin opportunities and potential earnings expansion."

The real swing factor is how one emerging pressure ultimately shapes the balance between those higher margins and the growth investors are hoping for.

That trade off between margin pressure and growth potential is exactly what the full narrative for Hikma Pharmaceuticals unpacks. It also explores where current pricing could be masking upside.

Oxford Biomedica (LSE:OXB)

Overview: Oxford Biomedica runs viral vector development and manufacturing for gene and cell therapies, built around its LentiVector and AAV platforms.

Operations: Oxford Biomedica generates about £60 million from Development Services, £88 million from Manufacturing Services, £22 million from Procurement, and £5 million from licences, milestones and royalties.

Market Cap: £620 million

Oxford Biomedica plugs into the Biotech Stocks theme as the behind the scenes specialist that supplies the viral vectors gene and cell therapy developers rely on. This allows investors to gain exposure to that pipeline activity without picking single drug programs.

"The increasing demand for their differentiated CDMO services, highlighted by a 35% rise in contracted client orders, positions OXB for sustained growth and an increase in overall revenue."

What really matters now is how one unresolved execution gap affects the point where that rising order book turns into durable margins.

That execution gap is the crux, and the full narrative for Oxford Biomedica shows how Oxford Biomedica could turn a swelling order book into accelerating, higher quality earnings power.

Genus (LSE:GNS)

Overview: Genus plc applies biotechnology to animal breeding by supplying dairy and pork genetics, including semen, embryos and breeding stock, to farmers worldwide.

Operations: Genus generates about £355.8 million from Genus PIC, £299.8 million from Genus ABS and £2.5 million from Central services.

Market Cap: £1.5b

For the Biotech Stocks theme, Genus gives you direct exposure to applied genetics in livestock, where lab driven gains show up in herd productivity.

"Although the PRP program is progressing through approvals in markets such as Canada, Mexico and Japan, planned PRP expenditure of about £13m in FY26 with a further increase guided for FY27 means cash outflows are locked in before revenue arrives."

What really moves the needle is how that upfront spend may reshape future pricing power and profit margins across Genus’s wider genetics portfolio.

That upfront spend only matters if it rewires future economics, and the full narrative for Genus shows how Genus could turn today’s drag into accelerating and compounding cash power.

Seeking Alternatives Beyond Biotech?

Fresh ideas do not stay under the radar for long. Strong businesses gain momentum, prices move, and ideal entry windows shrink fast. Scan these focused lists and get in early.

• Target durable cash generators by reviewing the list of solid balance sheet and fundamentals (9 results) to find companies with robust finances before the crowd catches on and prices start moving.
• Consider potential income-focused companies by scanning the 3 dividend fortresses while yields remain elevated and quality businesses have not been fully re-rated.
• Track the infrastructure behind tomorrow’s energy mix by checking the 16 nuclear energy infrastructure stocks while these under-the-radar operators are still priced for hesitation rather than momentum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com